Dr Allison Jeynes, MD, FFPM (UK)
Allison Jeynes, MD, FFPM (UK) is Chief Executive Officer at Avillion LLP, a London-based drug development company focused on the co-development and financing of late-stage pharmaceuticals. A trained clinician with more than 25 years of senior leadership experience in the pharmaceutical industry, she is now responsible for identifying high-potential opportunities to fund programs to approval. Previously, she led development at Wyeth, BMS, and Novartis and has secured numerous US and EU drug approvals. Allison also serves as a Non-Executive Director of Agenus Inc. and Anaveon AG and is a Senior Advisor to Blackstone Life Sciences and a Special Advisor to Abingworth. Allison became Non-Executive Chair of the OxSonics Board in April 2021.